A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 89
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : MD
Long Form : maintenance dose
No. Year Title Co-occurring Abbreviation
2019 Candidate gene and pathway analyses identifying genetic variations associated with prasugrel pharmacokinetics and pharmacodynamics. LD, PD, PK
2019 Critical Care Management of Status Epilepticus at a Tertiary Care University Hospital. AEDs, BDZs, LD, PHT, SE
2019 Optimizing vancomycin dosage regimens in relation to high-flux haemodialysis. HFHD, LD, PK, WBH
2019 Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. AMI, ELECTRA
2019 Venom allergy treatment practices in Poland in comparison to guidelines: next edition of the national audit. VIT
2018 Absence of differential effect of ticagrelor versus prasugrel maintenance dose on endothelial function in patients with stable coronary artery disease. CAD, ED, RHI
2018 Association of N6AMT1 rs2254638 Polymorphism With Clopidogrel Response in Chinese Patients With Coronary Artery Disease. CR, LD, N6AMT1, non-CR, PCI, PRI
2018 Efficacy and safety of low-dose heparin in hemodialysis. HD, LD, UFH
2018 Efficacy of a Standardized Oral Vitamin D Dosing Regimen in Nursing Home Residents. CI, LD, VDDR, VDTL
10  2018 Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study. LD
11  2018 Phenobarbital pharmacokinetics in neonates and infants during extracorporeal membrane oxygenation. BW, CL, CV, ECMO, LD, PK, TDM, Vd
12  2018 Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects. LD, PD, PK, SNPs
13  2018 Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp. LD, LT, PTA
14  2018 The effect of diet, adiposity, and weight loss on the secretion of incretin hormones in cats. AUC, GIP, GLP-1, RCD, SMT
15  2017 Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation. CRRT, ECMO, LD, PK
16  2016 A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. HPR, LD, PD
17  2016 Bleeding events and maintenance dose of prasugrel: BLESS pilot study. ACS, BARC, RPR
18  2016 Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. ACS, HTPR, LD, PCI, VASP
19  2016 Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients. PCI
20  2016 Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. AU, CI, HTPR, LD, PCI
21  2015 A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. CAD, LD, OTR, PD, PK
22  2015 High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention: a meta-analysis. CI, CV, HTPR, RR
23  2015 In vitro evaluation of allergen potencies of commercial house dust mite sublingual immunotherapy reagents. AU, HDM, IR, SLIT, STU
24  2015 Meta-analysis appraising high maintenance dose clopidogrel in patients who underwent percutaneous coronary intervention with and without high on-clopidogrel platelet reactivity. CI, HPR, OR, PCI
25  2015 Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. BMI, LD, PCI, PLT
26  2015 Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation. LD, PD, PRI
27  2015 Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. CAD, DM, LD
28  2015 Predictors of antiplatelet response to prasugrel during maintenance treatment. BMI, IQR, PA, PCI
29  2015 Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. HPR, LD, STEMI
30  2014 An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. CABG, HR, STEMI, TIA, UA/NSTEMI
31  2014 Comparison of loading with maintenance dose of clopidogrel on platelet reactivity in Chinese with different CYP2C19 genotypes prior to percutaneous coronary intervention. LD, PA, PCI
32  2014 Down-regulation of FcepsilonRI-mediated CD63 basophil response during short-term VIT determined venom-nonspecific desensitization. HDM
33  2014 Evaluation of the effects of a therapeutic renal diet to control proteinuria in proteinuric non-azotemic dogs treated with benazepril. ACEIs, ALB, CBC, PNAz, RDs, SBP, UPC
34  2014 Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. BMI, CAD, LD, PD, PRI
35  2014 Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). LD
36  2014 Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. BMI, LPR, PR
37  2014 Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. ---
38  2014 Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. ACS, BARC, HPR, PCI, PR
39  2013 Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. LD, PR
40  2013 Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation. AM, LD, VASP
41  2013 Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention. ACS, DAPT, LD, LTA, PCI
42  2013 Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. ACS, HPR, HPR, LD, MPA, PRI, SWAP
43  2013 Factors affecting residual platelet aggregation in prasugrel treated patients. ACS, HPI, HPR, PR
44  2012 Evaluation of a vancomycin dosing regimen for patients on high flux hemodialysis: an observational study. HFHD, LD
45  2012 Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. CAD, IPA, LD, PCI
46  2012 Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects. LD, PDs, PKs
47  2012 Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. ASCT, CR, DLTs, OR
48  2012 Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. HTPR, LD, PR, STEMI
49  2012 Short-term venom immunotherapy induces desensitization of FcepsilonRI-mediated basophil response. VIT
50  2012 The effects of age, isoflurane and sevoflurane on atracurium in lambs. LD
51  2011 A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. CAD, DM, LD, OPTIMUS
52  2011 Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. ADP, clopi-H4, EMs, LD, MPA, PMs
53  2011 Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. ADP, LD
54  2011 Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. AMI, CYP2C19, HPR
55  2010 Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. AMI
56  2010 Bee venom immunotherapy - how early is it effective? BV, VIT
57  2010 Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. ADP, AMI, HPPR, PCI, PR
58  2010 Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. ---
59  2010 Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. ACS, LD, SWAP, SWAP
60  2010 Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. ACS, ADP, LD, PCI
61  2010 The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. ADP, IPA, LD
62  2009 Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. ADP, LD, LTA, VASP, VN-P2Y12
63  2009 Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. CAD, LD, RM, VASP
64  2009 Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. IPA, LD, MPA
65  2009 Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. ADP, HPPR
66  2008 A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. LDs, LTA, MPA, VASP, VASP-PRI
67  2008 Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. ACS, AUC, IPA, LD
68  2008 Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. AM, LD, PD
69  2008 Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. Clop-AM, LD, MPA, Pras-AM, Pras-thiolactone
70  2008 Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. AUC, LD, MPA, PRI
71  2008 Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. LD, MPA
72  2008 The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. LD, LTA, POC, VN-P2Y12
73  2007 Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. LD
74  2007 Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. IPA, LD
75  2006 Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. CAD, IPA, LD
76  2006 The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. ADP, LD
77  2004 Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. DD, PEF
78  2004 Pharmacokinetics of theophylline in preterm neonates during the first month of life. CL, GA, Ke, LD, TH-PKP, Vd
79  2003 Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. SRs, VIT
80  2003 Specific immunotherapy for severe latex allergy. LRs, SIT, SPT, SR
81  1999 Opioid neurotoxicity: fentanyl-induced exacerbation of cerebral ischemia in rats. LD
82  1998 Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. AChE, AUC, DDVP, LD, tmax
83  1996 Opioid neurotoxicity: fentanyl dose-response effects in rats. LD, NSS
84  1996 Opioid neurotoxicity: neuropathologic effects in rats of different fentanyl congeners and the effects of hexamethonium-induced normotension. LD
85  1992 Effect of intravenous hypnotics on the actions of pipecuronium. LD
86  1990 Algorithm for short-term prescription of phenprocoumon. ---
87  1990 Anticonvulsant therapy increases fentanyl requirements during anaesthesia for craniotomy. ---
88  1990 Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. ---
89  1988 Warfarin dosage requirements: prospective clinical trial of a method for prediction from the response to a single dose. ---